BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933. The ...

Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

First, the acquisitions, which take the total number of companies snapped up by Ginkgo in the last few years to more than a dozen, extending the cell programming company's capabilities above and ...

"We're excited to embark on this collaboration, which represents a significant milestone for Ginkgo as we expand our cell therapy portfolio," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Ginkgo Bioworks imply an improvement in the company's underlying business. Investors should show their ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics ...